Abstract: Previous case reports have demonstrated that dupilumab can achieve rapid disease control in epidermolysis bullosa acquisita (EBA). In this case, a 7-year-old child with EBA showed poor response to long-term glucocorticoid therapy. Based on prior case reports, the patient was administered dupilumab in combination with methylprednisolone tablets 8 mg/day. After 12 weeks of treatment, the existing skin lesions dried up and formed crusts, the erosive lesions on the oral mucosa regressed, occasional new lesions only appeared at friction-prone sites, and pruritus was significantly alleviated. Currently, the glucocorticoid dose has been tapered to 4 mg/day, and the patient remains under continuous follow-up.

Key words: child, epidermolysis bullosa acquisita, dupilumab